二价 mRNA 疫苗在预防无症状 SARS-CoV-2 感染中的效果--增加社区接受检测计划的机会，美国，2023 年 1 月至 9 月。

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-11-10 DOI:10.1111/irv.70038

Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles

{"title":"二价 mRNA 疫苗在预防无症状 SARS-CoV-2 感染中的效果--增加社区接受检测计划的机会，美国，2023 年 1 月至 9 月。","authors":"Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles","doi":"10.1111/irv.70038","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550894/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023\",\"authors\":\"Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles\",\"doi\":\"10.1111/irv.70038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 11\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550894/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70038\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：2022 年 9 月 2 日，为解决 COVID-19 单价疫苗在 SARS-CoV-2 Omicron 变种占主导地位期间有效性降低的问题，推荐使用二价 COVID-19 mRNA 疫苗：本研究采用 2023 年 1 月 15 日至 9 月 11 日期间基于全国药房的 SARS-CoV-2 检测项目数据，对 COVID-19 二价疫苗预防无症状感染的有效性 (VE) 进行了评估：结果：接种二价疫苗后2周至1个月期间，接种二价疫苗对无症状感染的有效率为：年龄≥65岁者为46%（95% CI：38%-52%），12-17岁者为61%（95% CI：41%-75%）：结论：二价疫苗可预防无症状感染。结论：二价疫苗对无症状感染有保护作用，但随着时间的推移，效果会减弱，因此需要及时接种 COVID-19 疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023

查看原文本刊更多论文

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023

Background

On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.

Methods

Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.

Results

VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.

Conclusion

Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.